November 06, 2026

To, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 **Scrip Code**: **544889**	To, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 **Symbol**: **SYMBIOTEC**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached update titled "**Symbiotec Signs 10-Year Take-or-Pay Agreement to Manufacture Fermentation-Based Alternative Protein for EU Innovator**"

Further, the details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure A.**

This is for your Information and Records.

Thanking You,

Sincerely,
for **Symbiotec Pharmalab Limited**

SALIL JAIN
Digitally signed by SALIL JAIN
Date: 2026.11.06 09:44:52 +05'30'

Salil Jain
Company Secretary and Compliance Officer
Membership No. A41610

Registered Office & Works:
Symbiotec Pharmalab Limited
(Formerly known as Symbiotec Pharmalab Pvt. Ltd.)
385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India
Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,
Email ID : symbiotec@symbiotec.com, **Website** : www.symbiotec.com
CIN: U24232MP2002PLC015293

Symbiotec Signs 10-Year Take-or-Pay Agreement to Manufacture Fermentation-Based Alternative Protein for a European Alternative Protein Innovator

Indore, India, November 6, 2026: Symbiotec, a science-driven pharmaceutical and biotechnology company, today announced a 10-year, take-or-pay contract development and manufacturing agreement with a European alternative protein innovator. The agreement reserves dedicated capacity for the partner at Symbiotec's Ujjain campus for the full term.

Under the agreement, production will be based at Symbiotec's biomanufacturing campus in Ujjain, which features four 100 kilolitre (kL) fermenters, modular downstream processing, and integrated quality assurance and quality control capabilities. Production begins at the existing facility, with a new dedicated plant of several hundred thousand litres of fermentation capacity to follow, and contracted expansion options reserved for the partner that take the programme into the millions of litres.

Precision fermentation uses engineered microorganisms to produce proteins traditionally derived from animals. These ingredients must meet high-quality standards and be produced at a cost that allows wide adoption, two demands that usually pull against each other. Symbiotec brings both: the quality systems of a pharmaceutical manufacturer, and a long record of building and running its own fermentation plants at scale.

Commenting on the agreement, Mr. Anil Satwani, Managing Director, Symbiotec Pharmalab, said: "This fermentation-derived protein marks a major milestone in creating the clean, nutritious alternatives that consumers increasingly seek. We are well positioned to serve the alternative protein, human nutrition, and industrial bioproducts sectors.

"Biotechnology is fundamentally changing how everyday products are made. Our planet needs cleaner, greener ways to produce essentials, and we are glad to see the industry moving in that direction."

About Symbiotec Pharmalab

Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. Founded in 1995, the Company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs).

Symbiotec serves over 200 customers across more than 40 countries through three complementary business verticals — APIs, CDMO services and Complex Injectables — supported by four manufacturing facilities in Madhya Pradesh, India, with approvals from USFDA, EU-GMP, WHOGMP, Japan-PMDA and other leading global regulators.

Annexure A

Sr. No.	Particulars	Description
1.	Purpose of entering into the agreement	Strategic CDMO Agreement to Manufacture Fermentation-Based Alternative Protein for an European Innovator
2.	Name(s) of parties with whom the agreement is entered	A leading Alternative Protein European Innovator
3.	Area of agreement	10-year, take-or-pay contract development and manufacturing agreement.
4.	Domestic / International	International
5.	Significant terms of the agreement (in brief)	Under the agreement, production will be based at Symbiotec's biomanufacturing campus in Ujjain, which features four 100 kiloLitre (kL) fermenters, modular downstream processing, and integrated quality assurance and quality control capabilities.
6.	Details of consideration paid / received in agreement	Details cannot be disclosed due to confidentiality obligations
7.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	NA
8.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length	NA
9.	In case of issuance of shares to the parties, details of issue price, class of shares issued	NA

10.	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	NA
11.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc	NA

Registered Office & Works:
Symbiotec Pharmalab Limited
(Formerly known as Symbiotec Pharmalab Pvt. Ltd.)
385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India
Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,
Email ID : symbiotec@symbiotec.com, **Website** : www.symbiotec.com
CIN: U24232MP2002PLC015293